- |||||||||| fluorouracil / generics
Preclinical, Journal: An Organoid-Based Preclinical Model of Human Gastric Cancer. (Pubmed Central) - Apr 30, 2019
No abstract available The treatment of patient-derived organoids alongside patients from whom cultures were derived will ultimately test their usefulness to predict individual therapy response and patient outcome.
- |||||||||| doxorubicin hydrochloride / generics
Biomarker, Journal: Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. (Pubmed Central) - Apr 30, 2019
These findings establish chemotherapy-induced immunological dormancy in ER breast cancer as a novel concept for (neo)adjuvant chemotherapy activity, and implicate sustained activation of the IRF7/IFN-β/IFNAR pathway in this effect. Further, IFN-β emerges as a potential predictive biomarker and therapeutic molecule to improve outcome of ER breast cancer patients treated with (neo)adjuvant chemotherapy.
- |||||||||| metformin / Generic mfg.
Trial completion date, Trial primary completion date: NeoMET Study in Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Apr 20, 2019
P2, N=200, Recruiting,
Recruiting --> Completed | N=1664 --> 685 Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- |||||||||| paclitaxel / generics
Journal: Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. (Pubmed Central) - Apr 17, 2019
...Here, we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2780/PTX which is also cross resistant to the cisplatin and epirubicin...Interestingly, the multidrug resistant linked genes ABCB1, ABCB4, ABCC3 and ABCG2 are all co-expressed with lncRNA CTD-2589M5.4. Our results provide the valuable information for the understanding of the lncRNA function in the multidrug resistant process.
- |||||||||| epirubicin / generics
Journal: Laden Nanofiber Capsules for Local Malignancy Chemotherapy. (Pubmed Central) - Apr 16, 2019
...In this study, we developed a series of epirubicin (EPI)-loaded poly(ε-caprolactone)/poly(lactide-co-glycolide) (PCL/PLGA) nanofiber capsules with adjustable rates of drug release and degradation for local malignancy chemotherapy...Moreover, none of the laden nanofiber capsules caused apparent systemic toxicity. Hence, the cytostatic-loaded electrospun polyester nanofiber capsules displayed controlled drug release and degradation, along with satisfactory antitumor properties, indicating their great potential in local malignancy chemotherapy.
- |||||||||| Herceptin (trastuzumab) / Roche, Abraxane (albumin-bound paclitaxel) / Celgene, Otsuka
Clinical, P2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial. (Pubmed Central) - Apr 16, 2019
Hence, the cytostatic-loaded electrospun polyester nanofiber capsules displayed controlled drug release and degradation, along with satisfactory antitumor properties, indicating their great potential in local malignancy chemotherapy. Nab-paclitaxel plus trastuzumab followed by FEC in patients with HER2-positive operable breast cancer is considerably effective and well tolerated.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Clinical, Review, Journal: Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. (Pubmed Central) - Apr 14, 2019
There was considerable heterogeneity between trial design and duration of follow-up, making direct comparisons for recurrence, progression, and survival outcomes between trials challenging. Although maintenance intravesical chemotherapy is suggested as a treatment option for patients with NMIBC by some guidelines, the majority of evidence suggested that it provided no significant advantage over induction therapy alone with respect to recurrence, progression, or survival.
- |||||||||| epirubicin / generics
Review, Journal: Single postoperative instillation for non-muscle invasive bladder cancer: are there still any indication? (Pubmed Central) - Apr 13, 2019
...The efficacy of this procedure is particularly evident when epirubicin or mitomycin C is administered...Although it is a safe procedure, rare severe complications have been reported in the literature, mostly due to extravasation of drugs in patients who underwent extended resection or bladder perforation. To avoid potential deadly complications, SI should not be administered in these patients.
- |||||||||| cyclophosphamide intravenous / generics
Clinical, Journal: Three cases of non-Hodgkin's lymphoma in HIV-infected Bulgarian patients. (Pubmed Central) - Apr 11, 2019
The first patient received antiretroviral therapy (ART) and EPOCH (etoposide, pharmarubicin, vincristin, endoxane, uromitexan) plus radiotherapy, while the second received ART and CHOEP (endoxan, epirubicin, vincristin, etoposide, prednisolone). The third patient died a few days after beginning antiretroviral therapy.
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, P2 data, Journal: Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. (Pubmed Central) - Apr 10, 2019
P2
Cohort B patients received four standard fluorouracil/epirubicin/cyclophosphamide cycles, then four docetaxel cycles with four standard trastuzumab and pertuzumab cycles...Treatment with pertuzumab, trastuzumab, and common anthracycline-containing regimens for the neoadjuvant treatment of early breast cancer resulted in cardiac and general safety profiles, and pCR rates, consistent with prior studies with pertuzumab. NCT02132949.
- |||||||||| fluorouracil / generics, cyclophosphamide intravenous / generics
Review: Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers (Pubmed Central) - Apr 9, 2019
NCT02132949. ...subtypes and display better clinical outcome than triple negative breast cancers (TNBCs) with FEC (5-Fluorouracil,Epirubicin and Cyclophosphamide) the mainstay chemotherapy regiment...as providing insights on possible ways to utilize epigenetic enzymes/inhibitors with responses to chemotherapeuticdrugs to re-program cellular and biological outcome in TNBCs.
- |||||||||| Trial completion date, Trial primary completion date: COC-IDCB: A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (clinicaltrials.gov) - Apr 8, 2019
P1, N=300, Recruiting,
...subtypes and display better clinical outcome than triple negative breast cancers (TNBCs) with FEC (5-Fluorouracil,Epirubicin and Cyclophosphamide) the mainstay chemotherapy regiment...as providing insights on possible ways to utilize epigenetic enzymes/inhibitors with responses to chemotherapeuticdrugs to re-program cellular and biological outcome in TNBCs. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- |||||||||| paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, P3 data, Journal: Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial. (Pubmed Central) - Apr 5, 2019
A total of 1284 patients with 4 or more involved axillary lymph nodes were randomly assigned to receive 3 courses each of idd sequential epirubicin, paclitaxel and cyclophosphamide (iddEPC) q2w or standard epirubicin/cyclophosphamide followed by paclitaxel (EC → P) q3w...Nine vs. two cases of secondary myeloid leukaemia/MDS were observed in the iddEPC and the EC&cenveo_unknown_entity_wingdings_F0E0;P arm, respectively. The previously reported OS benefit of intense dose-dense EPC in comparison to conventionally dosed EC&cenveo_unknown_entity_wingdings_F0E0;P has been further increased and achieved an absolute difference of 10% after 10 years of follow-up.
- |||||||||| fluorouracil / generics, doxorubicin hydrochloride / generics, cyclophosphamide intravenous / generics
Clinical, Journal: Surgical Treatment and Chemotherapy of Adult Primary Liver Sarcoma: Experiences from a Single Hospital in China. (Pubmed Central) - Apr 5, 2019
The previously reported OS benefit of intense dose-dense EPC in comparison to conventionally dosed EC&cenveo_unknown_entity_wingdings_F0E0;P has been further increased and achieved an absolute difference of 10% after 10 years of follow-up. The diagnosis of PLS is difficult before operation due to its nonspecific manifestations, and the high survival rate can be achieved by radical resection with adjuvant chemotherapy.
- |||||||||| Tafinlar (dabrafenib) / Novartis
Journal: Interaction of Anticancer Drugs with Human Organic Anion Transporter hOAT4. (Pubmed Central) - Apr 4, 2019
Our results established that epirubicin hydrochloride and dabrafenib mesylate are inhibitors of hOAT4. Furthermore, by comparing our data with clinically relevant exposures of these drugs, we conclude that although the tendency for dabrafenib mesylate to cause drug-drug interaction through hOAT4 is insignificant in the kidney, the propensity for epirubicin hydrochloride to cause drug-drug interaction is high.
- |||||||||| Savene (dexrazoxane) / Kissei, Seelos Therap
Journal, Benefit-risk assessment: Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. (Pubmed Central) - Apr 3, 2019
We review here the evidence published since 2011, which confirms that dexrazoxane is an effective cardioprotectant in children and adolescents, is not associated with an increased risk of second primary malignancies or excess early or late mortality and does not impair chemotherapy efficacy. Based on this evidence, the contraindication for children and adolescents requiring high doses of anthracyclines and at risk for cardiotoxicity was removed from the European labeling for dexrazoxane.
- |||||||||| cyclophosphamide intravenous / generics, docetaxel / generics, epirubicin / generics
Biomarker, Clinical, Journal: Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer. (Pubmed Central) - Apr 3, 2019
Receiver operating characteristics (ROC) curve displayed a satisfactory predictive value for lower cardiotoxicity risk with area under curve (AUC) of 0.842 of the combination of the miR-17-5p and miR-20a expressions. In addition, let-7f,miR-126, miR-210 and miR-378 levels negatively correlated with cTnI expression, and let-7f and miR-130a expressions reversely correlated with NT-proBNP level.CONLUSIONS: miR-17-5p and miR-20a could be served as biomarkers for lower cardiotoxicity induced by EC-D neoadjuvant chemotherapy in BC patients.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion date, Trial primary completion date: Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma (clinicaltrials.gov) - Apr 2, 2019
P4, N=360, Recruiting,
In addition, let-7f,miR-126, miR-210 and miR-378 levels negatively correlated with cTnI expression, and let-7f and miR-130a expressions reversely correlated with NT-proBNP level.CONLUSIONS: miR-17-5p and miR-20a could be served as biomarkers for lower cardiotoxicity induced by EC-D neoadjuvant chemotherapy in BC patients. Trial completion date: Feb 2019 --> Dec 2019 | Trial primary completion date: Aug 2017 --> Dec 2019
- |||||||||| Prolia (denosumab) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: Denosumab as an add-on Neoadjuvant Treatment (GeparX) (clinicaltrials.gov) - Apr 1, 2019
P2, N=780, Active, not recruiting,
Trial completion date: Feb 2019 --> Dec 2019 | Trial primary completion date: Aug 2017 --> Dec 2019 Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Oct 2019
- |||||||||| epirubicin / generics
Journal: One-Pot Synthesis of Epirubicin-Capped Silver Nanoparticles and Their Anticancer Activity against Hep G2 Cells. (Pubmed Central) - Mar 20, 2019
The results showed that a layer of polymer epirubicin had formed around the silver nanoparticle, which was 30-40 nm in diameter. We further investigated the antitumor activity of the prepared epirubicin-capped silver nanoparticle, and the half maximal inhibitory concentration (IC) against Hep G2 cells was 1.92 μg/mL, indicating a good antitumor property of the nanoparticle at low dosage.
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial initiation date, Trial primary completion date: EORTC 1745-ETF-BCG: Adjuvant Palbociclib in Elderly Patients With Breast Cancer (clinicaltrials.gov) - Mar 13, 2019
P2, N=366, Not yet recruiting,
Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Jan 2031 --> May 2031 | Initiation date: Jan 2019 --> May 2019 | Trial primary completion date: Jan 2024 --> May 2024
|
